AEGIS (Accelerated Early staGe drug dIScovery) is a Marie Skłodowska - Curie Innovative Training Network (ITN) for early stage researchers (ESR) funded by the European Commission under the H2020 Programme, the EU framework programme for research and innovation.
A key research aim of AEGIS is improving the efficiency and success of early stage drug development by combining innovative methods and techniques to tackle difficult but promising targets (i.e. protein-protein interactions), as potentially valuable drug targets are often neglected due to the high risk associated with their validation. AEGIS is a collaborative action of 11 groups in 7 countries from academia and pharmaceutical industry, combining a balanced portfolio of excellent expertise knowledge of structural and computational based drug design.
AEGIS will provide a comprehensive and cross-disciplinary structured curriculum for doctoral students in early drug discovery. 15 doctoral thesis fellowships are available in the areas structural biology using NMR and crystallography, computational structural biology and medicinal chemistry.
Further information: www.aegis-itn.eu